Acute and Chronic States Due to Hallucinogenic Substance Consumption and Treatment Strategies
Keywords:
Hallucinogens, LSD, 5 HT2 receptor antagonistsAbstract
Hallucinogens which are also named as psychomimetics and psychodelics are substances whose consumption cause hallucinations, delusions and illusions. They can be synthtetic or may be found naturally. LSD (lysergic acid dietylamide) is a prototype of classical synthetic halucinogens which was firstly synthesized in 1938 by Albert Hoffman .
They are generally consumed orally because of high rate of absorption by this way. Tolerance to hallucinogens also begins very rapidly, thus, they are very rarley used over once or twice a week.
Mentioning most typical of hallucinogens, LSD, behavioral effects begin within a hour and reaches its peak effect in 2-4 hours . After 10-12 hours , patient gets back to hallucinogen free status with some dysphoria and fatigue.
Autonomic signs like piloerection, mydriazis, hyperreflexia , hypertension, hyperthermia may also be seen with halucinogens. Cross tolerence among different halucinogenic drugs also occur.
Psychopharmacologically, the hallucinogenic effect of these drugs are related to decreased serotonine turn over in brain. 5HT2 a receptor antagonists can inhibit the hallucinogenic effect . The lethal dose for humans is not known but generally considere as high. Deaths from hallucinogen abuse generally happen by accidents according to misperceptions during hallucinations. Magical thinking after chronic hallucinogen consumption may cause personality disorders especially among adolescents resulting with social withdrawal symptoms. Long term psychotherapy is indicated in such patients.
References
Abraham HD, Aldridge AM. Adverse consequences of lysergic acid diethylamide. Addiction 1993; 88: 1327-1334.
Pechnick RN, Ungerleider JT. Substance Abuse A Comprehensive Textbook. Hallucinogens. Lowin-son JH, Ruiz P, Millman RB, Langrod JG(editors).4. baskı, New York 2005: 313-323.
Sadock BJ, Sadock VA, Kaplan & Sadock Klinik Psikiyatri, Hamdullah A, Bozkurt A, Dilbaz N (Çe-viren-ler). 2. Baskı. Ankara: Güneş Kitabevi, 2005; 107-111.
Buckholtz NS, Zhou D, Freedman DX, et al. Lysergic acid diethylamide (LSD) administration selectively downregulates serotonin reseptors in rat brain. Neuropsychopharmacology 1990; 3: 137-148.
Halpern JH, Pope HG Jr. Hallusinogens of the Internet: a vast new source of underground drug information. Am J Psychiatry 2001; 158: 481-483.
Amerikan Psikiyatri Birliği: Psikiyatride Hastalıkların Tanımlanması ve Sınıflandırılması Elkitabı, Yeniden Gözden Geçirilmiş Dördüncü Baskı (DSM-IV-TR), Amerikan Psikiyatri Birliği, Washington DC, 2000’ den çeviren Köroğlu E, Hekimler Yayın Birliği, Ankara, 2001.
Strassman RJ. Hallucinogenic drugs in psychiatric research and treatment; perspectives and prospects. J Nerv Ment Dis 1995; 183: 127-138.
Ungerleider JT, Fisher DD, Goldsmith SR veark. A statistical survey of advers reactions to LSD in Los Angeles County. Am J Psychiatry 1968;125:352-357.
Abraham HD, Aldridge AM. LSD: a point well taken. Addiction 1994; 89: 763.
Işık E, Organik Psikiyatri,1. baskı, Ankara, Tayf Matbaası 1999: 470-476.
Aghajanian GK.Serotonin and the action of LSD in the brain. Psychiatr Ann 1994;24:137-141
Ungerleider JT, Fisher DD, Fuller MC, et al. The bad trip: the etiology of the adverse LSD reaction. Am J Psychiatry 1968; 125: 1483-1490.
Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, et al. Neurometabolic effects of psilocybin, 3-4-methylenedioxyethylamphetamine (MDE) and d-metamphetamine in healthy volunteers. Neuropsychopharmacology 1999; 20: 565-581.
Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans. I.Neuroendocrine, autonomic and cardiovascular effects. Arch Gen Psychiatry 1994;51.85-97.
Strassman RJ, Qualls CR. Dose-response study of N,N-dimethyltryptamine in humans.II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 1994; 51: 98-108.
Vollenweider FX, Vollenweider Scherpenhuyzen MFI, Babler A, et al. Psilocybin induces schizophrenia like psychosis in humans via a serotonin-2 agonist action. Neuroreport 1998; 9: 3897-3902.
Hermle L, Füngeld M, Oepen G, et al. Mescaline-induced psychopathological, neuropsychological and neurometabolic effects in normal subjects: experimental psychosis as a tool psychiatric research. Biol Psychiatry 1992; 32: 976-991.
Strassman RJ. Human hallucinogen interactions with drugs affecting serotonergic neurotransmission. Neuropsychopharmacology 1992; 7: 241243.
Abraham HD. A chronic impairment of colour vision in users of LSD. Br J Psychiatry 1982; 140: 518520.
Glennon RA. Do classical hallucinogens act as 5 HT2 agonists or antagonists? Neuropsychopharmacology 1990, 3: 509-517.
Perrine DM, Hallusinogens and obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 1123.
Abraham HD, Duffy FH. EEG coherence in postLSD visual hallucinations. Psychiatry Res 2001; 107: 151-163.
Alcantara AG. Is the a rol of alpha-2 antagonism in the exacerbation of hallucinogen-persisting perception disorder with risperidone. J Clin Psychop-harmacol 1998; 18:487-488
AldurraG,CraytonJW.Imptovementofhallucinogen persisting perception disorder by treatment with a combination of fluoxetine and olanzapine:case report. J Clin Psychopharmacol 2001; 21: 343-344.
Madden JS. LSD and post-hallucinogen perceptual disorder. Addiction 1994; 86: 762-763.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Journal of Dependence

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
...